Global Anti-Fungal Treatment Market By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Pyrimidines), By Indication (Systemics, Candidiasis, Cryptococcosis, Prophylactic Use of Antifungals, Coccidioidomycosis), By Pathogen (Candid, Aspergillus, Cryptococcus, CoccidiodiesImmitis, Zygomycetes, Trichophytons), By End-User (Hospitals & Clinics, Dermatology, Clinics), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2031
- Published date: Jan 2022
- Report ID: 73787
- Number of Pages: 365
- Format:
- keyboard_arrow_up
- 1.Anti-Fungal Treatment Market Introduction
- 1.1.Definition
- 1.2.Taxonomy
- 1.3.Research Scope
- 2.Executive Summary
- 2.1.Key Findings by Major Segments
- 2.2.Top strategies by Major Players
- 3.Global Anti-Fungal Treatment Market Overview
- 3.1.Anti-Fungal Treatment Market Dynamics
- 3.1.1.Drivers
- 3.1.2.Opportunities
- 3.1.3.Restraints
- 3.1.4.Challenges
- 3.2.COVID-19 Impact Analysis
- 3.3.COVID-19 Impact Analysis in Global Anti-Fungal Treatment Market
- 3.4.PESTLE Analysis
- 3.5.Opportunity Map Analysis
- 3.6.PORTER'S Five Forces Analysis
- 3.7.Market Competition Scenario Analysis
- 3.8.Product Life Cycle Analysis
- 3.9.Opportunity Orbits
- 3.10.Manufacturer Intensity Map
- 3.11.Major Companies sales by Value & Volume
- 3.1.Anti-Fungal Treatment Market Dynamics
- 4.Global Anti-Fungal Treatment Market Value (US$ Mn), Share (%), and Growth Rate (%) Comparison by Drug Class, 2015-2031
- 4.1.Global Anti-Fungal Treatment Market Analysis by Drug Class: Introduction
- 4.2.Market Size and Forecast by Region
- 4.3.Azoles
- 4.4.Echinocandins
- 4.5.Polyenes
- 4.6.Allylamines
- 4.7.Pyrimidines
- 5.Global Anti-Fungal Treatment Market Value (US$ Mn), Share (%), and Growth Rate (%) Comparison by Indication, 2015-2031
- 5.1.Global Anti-Fungal Treatment Market Analysis by Indication: Introduction
- 5.2.Market Size and Forecast by Region
- 5.3.Systemics
- 5.4.Candidiasis
- 5.5.Cryptococcosis
- 5.6.Prophylactic Use of Antifungals
- 5.7.Coccidioidomycosis
- 6.Global Anti-Fungal Treatment Market Value (US$ Mn), Share (%), and Growth Rate (%) Comparison by Pathogen, 2015-2031
- 6.1.Global Anti-Fungal Treatment Market Analysis by Pathogen: Introduction
- 6.2.Market Size and Forecast by Region
- 6.3.Candid
- 6.4.Aspergillus
- 6.5.Cryptococcus
- 6.6.CoccidiodiesImmitis
- 6.7.Zygomycetes
- 6.8.Trichophytons
- 7.Global Anti-Fungal Treatment Market Value (US$ Mn), Share (%), and Growth Rate (%) Comparison by End-User, 2015-2031
- 7.1.Global Anti-Fungal Treatment Market Analysis by End-User: Introduction
- 7.2.Market Size and Forecast by Region
- 7.3.Hospitals & Clinics
- 7.4.Dermatology
- 7.5.Clinics
- 8.Global Anti-Fungal Treatment Market Value (US$ Mn), Share (%), and Growth Rate (%) Comparison by Region, 2015-2031
- 8.1.North America
- 8.1.1.North America Anti-Fungal Treatment Market: Regional Trend Analysis
- 8.1.1.1.U.S.
- 8.1.1.2.Canada
- 8.1.1.3.Mexico
- 8.1.1.North America Anti-Fungal Treatment Market: Regional Trend Analysis
- 8.2.1.Europe
- 8.2.1.Europe Anti-Fungal Treatment Market: Regional Trend Analysis
- 8.2.1.1.U.K.
- 8.2.1.2.Germany
- 8.2.1.3.France
- 8.2.1.4.Spain
- 8.2.1.5.Italy
- 8.2.1.6.Russia
- 8.2.1.7.Rest of Europe
- 8.2.1.Europe Anti-Fungal Treatment Market: Regional Trend Analysis
- 8.3.Asia-Pacific
- 8.3.1.Asia-Pacific Anti-Fungal Treatment Market: Regional Trend Analysis
- 8.3.1.1.China
- 8.3.1.2.Japan
- 8.3.1.3.South Korea
- 8.3.1.4.India
- 8.3.1.5.ASEAN
- 8.3.1.6.Rest of Asia-Pacific
- 8.3.1.Asia-Pacific Anti-Fungal Treatment Market: Regional Trend Analysis
- 8.4.Latin America
- 8.4.1.Latin America Anti-Fungal Treatment Market: Regional Trend Analysis
- 8.4.1.1.Brazil
- 8.4.1.2.Argentina
- 8.4.1.3.Rest of Latin America
- 8.4.1.Latin America Anti-Fungal Treatment Market: Regional Trend Analysis
- 8.5.Middle East and Africa
- 8.5.1.Middle East and Africa Anti-Fungal Treatment Market: Regional Trend Analysis
- 8.5.1.1.GCC
- 8.5.1.2.Israel
- 8.5.1.3.South Africa
- 8.5.1.4.Rest of MEA
- 8.5.1.Middle East and Africa Anti-Fungal Treatment Market: Regional Trend Analysis
- 8.1.North America
- 9.Global Anti-Fungal Treatment Market Competitive Landscape, Market Share Analysis, and Company Profiles
- 9.1.Market Share Analysis
- 9.2.Company Profiles
- 9.3.Pfizer Inc.
- 9.3.1.Company Overview
- 9.3.2.Financial Highlights
- 9.3.3.Product Portfolio
- 9.3.4.SWOT Analysis
- 9.3.5.Key Strategies and Developments
- 9.4.Astellas Pharma Ltd.
- 9.4.1.Company Overview
- 9.4.2.Financial Highlights
- 9.4.3.Product Portfolio
- 9.4.4.SWOT Analysis
- 9.4.5.Key Strategies and Developments
- 9.5.Novartis International AG
- 9.5.1.Company Overview
- 9.5.2.Financial Highlights
- 9.5.3.Product Portfolio
- 9.5.4.SWOT Analysis
- 9.5.5.Key Strategies and Developments
- 9.6.Sanofi S.A.
- 9.6.1.Company Overview
- 9.6.2.Financial Highlights
- 9.6.3.Product Portfolio
- 9.6.4.SWOT Analysis
- 9.6.5.Key Strategies and Developments
- 9.7.Merck KGaA
- 9.7.1.Company Overview
- 9.7.2.Financial Highlights
- 9.7.3.Product Portfolio
- 9.7.4.SWOT Analysis
- 9.7.5.Key Strategies and Developments
- 9.8.Bayer AG
- 9.8.1.Company Overview
- 9.8.2.Financial Highlights
- 9.8.3.Product Portfolio
- 9.8.4.SWOT Analysis
- 9.8.5.Key Strategies and Developments
- 9.9.Abbott Laboratories
- 9.9.1.Company Overview
- 9.9.2.Financial Highlights
- 9.9.3.Product Portfolio
- 9.9.4.SWOT Analysis
- 9.9.5.Key Strategies and Developments
- 9.10.Janssen Pharmaceuticals
- 9.10.1.Company Overview
- 9.10.2.Financial Highlights
- 9.10.3.Product Portfolio
- 9.10.4.SWOT Analysis
- 9.10.5.Key Strategies and Developments
- 9.11.Gilead Sciences Inc.
- 9.11.1.Company Overview
- 9.11.2.Financial Highlights
- 9.11.3.Product Portfolio
- 9.11.4.SWOT Analysis
- 9.11.5.Key Strategies and Developments
- 9.12.Cipla Inc.
- 9.12.1.Company Overview
- 9.12.2.Financial Highlights
- 9.12.3.Product Portfolio
- 9.12.4.SWOT Analysis
- 9.12.5.Key Strategies and Developments
- 10.Assumptions and Acronyms
- 11.Research Methodology
- 12.Contact
- 1.Anti-Fungal Treatment Market Introduction
- Pfizer Inc Company Profile
- Astellas Pharma Ltd.
- Novartis AG Company Profile
- Sanofi S.A.
- Merck KGaA Company Profile
- Bayer AG Company Profile
- Abbott Laboratories
- Janssen Pharmaceuticals
- Gilead Sciences Inc.
- Cipla Inc.
- others
- settingsSettings
Our Clients
- 73787
- Jan 2022
-
US $5,999US $2,999
-
US $7,999US $3,499
-
US $12,999US $4,499
✖
Request a Sample Report
We'll get back to you as quickly as possible|
Single User
$5,999
$2,999
USD / per unit
save 50% |
Multi User
$7,999
$3,499
USD / per unit
save 55% |
Corporate User
$12,999
$4,499
USD / per unit
save 65% | |
|---|---|---|---|
| e-Access | |||
| Data Set (Excel) | |||
| Company Profile Library Access | |||
| Interactive Dashboard | |||
| Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
| Accessibility | 1 User | 2-5 User | Unlimited |
| Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
| Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
| Buy Now ($ 2,999) | Buy Now ($ 3,499) | Buy Now ($ 4,499) |
